Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nasal insulin study aims to uncover Obesity's hidden effects on brain and blood flow

NCT ID NCT07653464

Knowledge-focused Sponsor: University of Missouri-Columbia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This early-phase study will test how insulin given as a nasal spray affects nerve activity and blood flow in the brain and legs. Researchers will compare 64 adults with obesity and insulin resistance to healthy-weight individuals. The goal is to understand how obesity changes the body's response to insulin beyond blood sugar control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
human insulin (given as a nasal spray)
What this could lead to
If successful, this study could reveal how obesity-related insulin resistance alters brain and blood vessel responses, pointing toward new ways to manage metabolic health.
What could go wrong
This is a very early, small study (64 people) that only measures short-term nerve and blood flow changes, not health outcomes. It may not lead to any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 64 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jun 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 to 65 years of age Individuals with obesity and comorbid IR * BMI 30-45 kg/m2 * Waist circumference ≥102 cm (men) or ≥88 cm (women) * HOMA-IR ≥2.5 Healthy normal weight adults * BMI 18-25 kg/m2 * Waist circumference \<94 cm (men) and \<80 cm (women) * HOMA-IR \<2 Exclusion Criteria: * Pregnancy, breastfeeding * Unable to provide consent * Diabetes or polycystic ovarian syndrome * Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease, stroke * Nerve/neurologic disease * Uncontrolled hypertension (systolic blood pressure \>180 mmHg and/or diastolic blood pressure \>100 mmHg) * Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin) * Current smoking, tobacco, nicotine use * Use of pharmacological therapy for weight loss * Body weight change \>10% within the last 6 months * Adherence to \>150 min/week of moderate-to-vigorous physical activity/exercise * Participation in any other research study or medical procedure involving significant ionizing radiation exposure in the past 12 months * Claustrophobia * Non-MRI compatible metal implants

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance Obesity (bmi>30)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Missouri

    Columbia, Missouri, 65211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.